ArticleClinical medicine insights. Endocrinology and diabetes2021

Multicenter, Open-Label, 2-Arm, Pilot Trial for Safe Reduction of Basal Insulin Dose Combined with SGLT2 Inhibitor in Type 1 Diabetes Mellitus: Study Protocol for a RISING-STAR Trial.

Masahide Hamaguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.